ArticleScientific reports2017
A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Predictive biosignatures for hospitalization in patients with virologically confirmed COVID-19.Journal of the Chinese Medical Association : JCMA · 2025Article
- HCC biomarkers - state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice.Frontiers in oncology · 2022Review
- Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts.Advances in cancer research · 2022Article
- Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.PloS one · 2022Article
- Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients.BMC gastroenterology · 2021Article
- Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure.JHEP reports : innovation in hepatology · 2021Article
- Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk.Journal of clinical medicine · 2020Review
- Downregulation of exosomal miR‑1273a increases cisplatin resistance of non‑small cell lung cancer by upregulating the expression of syndecan binding protein.Oncology reports · 2020Article
- Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis.World journal of gastrointestinal oncology · 2020Article
- Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients.Digestive diseases and sciences · 2020Article
- Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis.World journal of gastroenterology · 2020Review
- High expression of IGF2-derived intronic miR-483 predicts outcome in hepatoblastoma.Cancer biomarkers : section A of Disease markers · 2020Observational
- Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma.OncoTargets and therapy · 2020Article
- miR‑218 functions as a tumor suppressor gene in cervical cancer.Molecular medicine reports · 2020Article
- Comprehensive transcriptomic analyses of tissue, serum, and serum exosomes from hepatocellular carcinoma patients.BMC cancer · 2019Article
- Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma.International journal of molecular sciences · 2019Article
- Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.World journal of hepatology · 2019Review
- Review
- Review
- A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the availability of potent antiviral therapies, complete suppression of hepatitis B virus (HBV) replication and total eradication of hepatitis C virus (HCV) can now be achieved. Despite these advances, hepatocellular carcinoma (HCC) still develops in a substantial proportion of cirrhotic patients, suggesting that host factors remain critical. Dysregulation of miRNAs is noted in many cancers, and circulating miRNAs can be readily assayed. In this study, we aimed to develop a circulating miRNA signature to assess the risk of HCC in cirrhotic patients. We first discovered that HBV- and HCV-related cirrhotic patients had distinguishable circulating miRNA profiles. A cohort of 330 cirrhotic patients was then compared against a cohort of 42 early HCC patients with complete remission. A score comprising 5 miRNAs and a binary etiology variable was established that was capable of differentiating between these two groups (AUC = 72.5%, P < 0.001). The 330 cirrhotic patients were further stratified into high- and low-risk groups, and all patients were longitudinally followed for 752 (11-891) days. Of them, 19 patients developed HCC. The high-risk group had significantly higher cumulative HCC incidence (P = 0.038). In summary, a circulating miRNA-based score was developed that is capable of assessing HCC risks in cirrhotic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.